Sugi Predict

Sugi Predict / Compounds / SCHEMBL758730

SCHEMBL758730

SCHEMBL758730

CC1CC(=O)C=CN1C(=O)OC(C)(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NFKB1 P19838 2/20 0.42
▸ NFKB2 Q00653 2/20 0.42
▸ RELA Q04206 2/20 0.42
▸ SETD7 Q8WTS6 2/20 0.40
▸ MAPK1 P28482 1/20 0.39
▸ NPC1 O15118 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ THRB P10828 1/20 0.36
▸ PTPN2 P17706 1/20 0.36
▸ PTPN1 P18031 1/20 0.36
▸ PTPN6 P29350 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ CHRM2 P08172 1/20 0.35
▸ CHRM1 P11229 1/20 0.35
▸ CHRM3 P20309 1/20 0.35
▸ GPR119 Q8TDV5 1/20 0.35
▸ STS P08842 3/20 0.34
▸ HSD11B1 P28845 1/20 0.34
▸ GLA P06280 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5470339 0.83 TSHR (0.44) NFKB1NFKB2RELAKMT2A
SCHEMBL3943561 0.80 NR1H2 (0.40) NFKB1NFKB2RELASETD7MAPK1
SCHEMBL760600 0.80 GLA (0.40) NFKB1NFKB2RELASETD7MAPK1
SCHEMBL4069068 0.79 TSHR (0.33) GPR119
SCHEMBL30534268 0.79 NFKB1 (0.38) NFKB1NFKB2RELASETD7NPC1
SCHEMBL5742136 0.79 NFKB1 (0.41) NFKB1NFKB2RELASETD7MAPK1
SCHEMBL7127132 0.79 PTPN1 (0.41) NFKB1NFKB2RELAMAPK1NPC1
SCHEMBL4166884 0.79 NFKB1 (0.41) NFKB1NFKB2RELASETD7MAPK1
SCHEMBL19765489 0.78 NOTUM (0.35) NFKB1NFKB2RELAMAPT
SCHEMBL12488873 0.78 P2RX7 (0.34) NFKB1NFKB2RELA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12551490-B2 Heterocyclic modulators of lipid synthesis SAGIMET BIOSCIENCES INC. (US) 2026-02-17 — — US disclosed
US-20240400552-A1 HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS SAGIMET BIOSCIENCES INC. 2024-12-05 — — US disclosed
US-20230405016-A1 HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS SAGIMET BIOSCIENCES INC. 2023-12-21 — — US disclosed
CN-116139138-A Heterocyclic modulators of lipid synthesis 3-V生物科学股份有限公司 2023-05-23 — — CN disclosed
CN-110177551-B Heterocyclic modulators of lipid synthesis 3-V生物科学股份有限公司 2023-02-17 — — CN disclosed
US-20220340556-A1 HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS SAGIMET BIOSCIENCES INC. 2022-10-27 — — US disclosed
US-20220296605-A1 HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS SAGIMET BIOSCIENCES INC. 2022-09-22 — — US disclosed
US-11034690-B2 Heterocyclic modulators of lipid synthesis Saginiet Biosciences Inc. (US) 2021-06-15 — — US disclosed
US-11034690-B2 Heterocyclic modulators of lipid synthesis Saginiet Biosciences Inc. (US) 2021-06-15 — — US disclosed
EP-3190108-B1 HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS SAGIMET BIOSCIENCES INC (US) 2021-05-19 — — EP disclosed
US-20120208816-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2012-08-16 — — US disclosed
US-20120208816-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2012-08-16 — — US disclosed
EP-2463282-A1 4-Benzylamino-1-carboxyacyl-piperidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis Novartis AG (CH) 2012-06-13 — — EP disclosed
US-8193349-B2 4-benzylamino-1-carboxylacyl-piperidine derivatives as CETP inhibitors NOVARTIS AG (CH) 2012-06-05 — — US disclosed
US-8193349-B2 4-benzylamino-1-carboxylacyl-piperidine derivatives as CETP inhibitors NOVARTIS AG (CH) 2012-06-05 — — US disclosed
US-8193349-B2 4-benzylamino-1-carboxylacyl-piperidine derivatives as CETP inhibitors NOVARTIS AG (CH) 2012-06-05 — — US disclosed
EP-2207775-B1 4-BENZYLAMINO-1-CARBOXYACYL-PIPERIDINE DERIVATIVES AS CETP INHIBITORS USEFUL FOR THE TREATMENT OF DISEASES SUCH AS HYPERLIPIDEMIA OR ARTERIOSCLEROSIS NOVARTIS AG (CH) 2012-03-21 — — EP disclosed
US-20090118287-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-05-07 — — US disclosed
US-20090118287-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-05-07 — — US disclosed
US-20090118287-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-05-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220340556-A1 HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS FASN, FADS1, FADS2 NFKB1 2301/4885NFKB2 2142/4885RELA 1179/4885
US-20230405016-A1 HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS FASN, FADS1, FADS2 NFKB1 1714/4885NFKB2 1668/4885RELA 844/4885
US-20240400552-A1 HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS FASN, FADS1, FADS2 NFKB1 2301/4885NFKB2 2142/4885RELA 1179/4885
US-11034690-B2 Heterocyclic modulators of lipid synthesis FASN, FADS1, SCD NFKB1 1792/4885NFKB2 1729/4885RELA 955/4885
US-20220296605-A1 HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS FASN, FADS1, SCD NFKB1 1792/4885NFKB2 1729/4885RELA 955/4885
US-20090118287-A1 ORGANIC COMPOUNDS CETP, NPC1, CES1 NFKB1 2700/4885NFKB2 2647/4885RELA 986/4885
US-12551490-B2 Heterocyclic modulators of lipid synthesis FASN, FADS1, FADS2 NFKB1 3137/4885NFKB2 3249/4885RELA 1432/4885
US-20120208816-A1 ORGANIC COMPOUNDS CETP, NPC1, CES1 NFKB1 2700/4885NFKB2 2647/4885RELA 986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.